Prospective Study of FGFR3 Mutations As a Prognostic Factor in Nonmuscle Invasive Urothelial Bladder Carcinomas

Abstract

The findings of this large study strongly support the notion that FGFR3 mutations characterize a subgroup of bladder cancers with good prognosis; patients with mutant TaG1 tumors have a higher risk of recurrence; and the F386L variant is selectively associated with low-grade tumors.

FGFR3 mutations in prostate cancer: association with low-grade tumors

“…Mutations in this gene have been reported in bladder and cervix carcinoma, multiple myeloma, colon cancer and, more recently, in benign skin tumors. [25][26][27][28][29][30][31][32][33] The relatively high prevalence of FGFR3 mutations in benign skin tumors and in noninvasive bladder tumors suggests an association of FGFR3 mutation with low risk cancers. 35,41 Although it seems that anomalous FGF signaling is involved in prostate carcinogenesis, the functional role of FGFR3 and its alterations in prostate cancer are unknown.…”

“…It is well known that FGFR3 mutations are frequent in superficial tumors but not in muscle-invasive tumors. [27][28][29]35 Thus, another possible explanation for the discrepant mutational status of FGFR3 in the bladder and prostate tumors could be that the bladder tumor had lost the mutated FGFR3 allele along its progression.…”

“…However, it has been associated with bladder tumors classified as low malignant potential neoplasms. 25,29,35 In SK, the A393E substitution has been reported with a frequency of about 9% of the adenoid SK harboring FGFR3 mutations. 45 In sharp contrast with the inhibitory role of the mutated forms of the FGFR3 gene in bone growth, FGFR3 mutations have been suggested to play an oncogenic role in human tumors.…”

“…[22][23][24] FGFR3 mutations identical to those found in these disorders have been reported in multiple myelomas, cervix and bladder cancer, colon cancer, and benign skin tumors. [25][26][27][28][29][30][31][32][33] This gene constitutes a promising marker in the clinical management of patients with low-grade, non-muscle-invasive bladder tumors. 29 However, very few authors have analyzed the mutational status of the FGFR3 gene in prostate tumors.…”

“…[25][26][27][28][29][30][31][32][33] This gene constitutes a promising marker in the clinical management of patients with low-grade, non-muscle-invasive bladder tumors. 29 However, very few authors have analyzed the mutational status of the FGFR3 gene in prostate tumors. 26,34 In this study, we have investigated the prevalence of FGFR3 somatic mutations, as well as the association with the presence of other concurrent neoplasms, in a large group of well-defined prostate tumors classified by combined Gleason score.…”